NDRA ENDRA Life Sciences Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1681682 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY27.0%
TTM EPS YoY-126.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-217.7%
ROA-134.7%
ROIC (approx.)-360.8%
Asset turnover—
Leverage & solvency
Liabilities / assets22.6%
Debt / equity0.00x
Current ratio7.95x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $176,280 | $233,665 | $776,410 | $508,137 | $432,113 | $381,061 | $528,685 | $637,957 |
| SG&A expense | $1.54M | $1.24M | $1.39M | $1.11M | $893,305 | $851,195 | $871,606 | $3.57M |
| Operating income | -$1.72M | -$1.48M | -$2.17M | -$1.62M | -$1.37M | -$1.30M | -$1.47M | -$4.30M |
| Pretax income | -$1.53M | $159,944 | -$1.31M | -$3.17M | -$1.60M | -$1.23M | -$1.04M | -$4.15M |
| Income tax | — | — | — | — | — | $0 | $0 | $0 |
| Net income | -$1.53M | $159,944 | -$1.31M | -$3.17M | -$1.60M | -$1.23M | -$1.04M | -$4.15M |
| EBITDA | -$1.71M | -$1.48M | -$2.16M | -$1.61M | -$1.36M | -$1.29M | -$1.46M | -$4.29M |
| EPS (basic) | -1.02 | 0.12 | -1.09 | — | -2.10 | -1.71 | -1.86 | — |
| EPS (diluted) | -1.02 | 0.06 | -1.09 | — | -2.10 | -1.71 | -1.86 | — |
| Weighted avg. shares (diluted) | 1.50M | 2.48M | 1.20M | — | 761,218 | 717,107 | 557,582 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.52M | $1.74M | $356,462 | $762,365 | $794,036 | $1.81M | $2.06M | $3.23M |
| Inventory | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Current assets | $5.05M | $5.59M | $536,666 | $967,969 | $1.05M | $1.85M | $2.18M | $3.43M |
| PP&E, net | $35,603 | $43,538 | $33,024 | $42,516 | $52,633 | $63,419 | $63,419 | $69,281 |
| Total assets | $6.72M | $7.94M | $3.44M | $3.85M | $1.96M | $2.81M | $3.17M | $4.45M |
| Current liabilities | $635,724 | $786,578 | $835,440 | $750,956 | $800,307 | $576,637 | $565,785 | $605,230 |
| Short-term debt | — | — | — | — | — | — | — | $0 |
| Long-term debt | — | — | — | — | — | — | — | $0 |
| Total debt | — | — | — | — | — | — | — | $0 |
| Total liabilities | $1.52M | $1.63M | $1.65M | $1.59M | $1.79M | $1.33M | $1.42M | $1.89M |
| Shareholders' equity | $5.20M | $6.31M | $1.79M | $2.26M | $171,380 | $1.47M | $1.75M | $2.56M |
| Net debt | — | — | — | — | — | — | — | -$3.23M |
| Shares outstanding | 1.50M | 1.50M | 1.24M | 1.18M | 786,902 | 752,390 | 562,213 | 536,908 |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.75M | -$927,560 | -$1.12M | -$1.61M | -$1.16M | -$1.11M | -$1.29M | -$1.52M |
| Capital expenditure | $0 | — | — | $0 | $0 | $0 | $17,280 | $0 |
| Free cash flow | -$1.75M | — | — | -$1.61M | -$1.16M | -$1.11M | -$1.31M | -$1.52M |
| Investing cash flow | $1.15M | $2.22M | $450,000 | -$3.00M | $0 | $0 | -$17,280 | $0 |
| Financing cash flow | $0 | $3.89M | $263,747 | $4.58M | $149,466 | $857,415 | $145,803 | $0 |
| Depreciation & amortization | $7,935 | $8,156 | $9,492 | $10,117 | $10,786 | $9,356 | $13,786 | $11,000 |
| Stock-based compensation | $357,007 | $541,904 | $574,451 | $12,878 | $144,722 | $39,530 | $83,046 | $104,684 |
Free plan shows the latest 8 periods; Pro shows all 43 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.